NCT06956170 · OUTCOME

Overall Survival (OS)

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma · Source last updated 2026-06-12

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to approximately 407 weeks

What was measured

Overall Survival (OS) defined as the interval of time from randomization to the date of death due to any cause.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2030-11
denom Units Selected: Participants
description: Overall Survival (OS) defined as the interval of time from randomization to the date of death due to any cause.
reporting Status: NOT_POSTED
time Frame: Up to approximately 407 weeks
title: Overall Survival (OS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice